Abstract: A novel PTH(1-34) mimetic peptide based on protein domain reconstruction. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. The amino acid at the 34th position and the last amino acid of the peptide fragment repeats at the 29th-34th positions are changed from phenylalanine (Phe, F) into tyrosine (Tyr, Y), so that MY-3 peptide is formed. Preclinical experiments show that the MY-3 mimetic peptide promotes osteoblast differentiation and has a very good effect in treating osteoporosis and promoting bone growth. The anti-osteoporosis effect of the MY-3 mimetic peptide is better than that of the PTH (1-34) (The product name on the market is Forsteo or Parathyroid), so that the MY-3 mimetic peptide has a significant clinical application prospect.

Abstract: The present disclosure belongs to the technical field of sewage treatment, and relates to a preparation method and use of a cobalt nanoparticle/boron nitride composite. The preparation method includes the following steps: dissolving 2-methylimidazole and boric acid in deionized water, and stirring to obtain a solution A; dissolving Co(NO3)2·6H2O and Zn(NO)3·6H2O in deionized water, and conducting ultrasonic dispersion to obtain a solution B; transferring the solution B into the solution A, and stirring to form a clear and transparent solution; transferring the clear and transparent solution into a container lined with Teflon, and conducting a reaction; subjecting an obtained product to cooling, filtration, washing, and drying sequentially to obtain a precursor of the composite; and conducting roasting on the precursor in an ammonia gas atmosphere to obtain the cobalt nanoparticle/boron nitride composite with a spherical superstructure.

Abstract: A novel PTH(1-34) mimetic peptide based on protein domain reconstruction. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. The amino acid at the 34th position and the last amino acid of the peptide fragment repeats at the 29th-34th positions are changed from phenylalanine (Phe, F) into tyrosine (Tyr, Y), so that MY-3 peptide is formed. Preclinical experiments show that the MY-3 mimetic peptide promotes osteoblast differentiation and has a very good effect in treating osteoporosis and promoting bone growth. The anti-osteoporosis effect of the MY-3 mimetic peptide is better than that of the PTH (1-34) (The product name on the market is Forsteo or Parathyroid), so that the MY-3 mimetic peptide has a significant clinical application prospect.